Laurus Labs has announced the receipt of the Establishment Inspection Report (EIR) from the United States Food & Drug Administration (USFDA) for its API manufacturing facility, Unit–4, located at Atchutapuram, Anakapalli District, Visakhapatnam, Andhra Pradesh.
The inspection was conducted by the USFDA from January 27 to January 31, 2025. The EIR confirms the completion of the inspection process and indicates the current compliance status of the facility with applicable US regulatory requirements.
This development follows Laurus Labs’ earlier intimation dated January 31, 2025, regarding the conclusion of the USFDA inspection at the site.
Unit–4 is one of Laurus Labs’ key active pharmaceutical ingredient (API) manufacturing sites, contributing to its global supply chain operations.
In the meantime, Laurus Labs shares opened at ₹611.55, reaching a high of ₹622.90 and a low of ₹608.80 during the session. The stock remains close to its 52-week high of ₹646.20, reflecting strong investor interest. With a 52-week low of ₹385.45, Laurus Labs has shown impressive recovery and momentum.
